Current Liabilities
Accounts Payable
Royalty Pharma Accounts Payable increased by 31.3% to $25.48M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 32.3%, from $37.63M to $25.48M. Over 5 years (FY 2020 to FY 2025), Accounts Payable shows an upward trend with a 12.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
An increase can signal improved cash management or extended payment terms, while a decrease may indicate faster payments to suppliers or reduced purchasing activity.
Detailed definition
This represents the short-term obligations owed to suppliers and vendors for goods and services received on credit. It i...
Peer comparison
Standard current liability for all companies; comparable across industries based on days payable outstanding.
Metric ID:
accounts_payableHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.39M | $9.19M | $5.62M | $6.66M | $12.18M | $16.11M | $7.91M | $6.66M | $5.81M | $13.63M | $15.17M | $11.55M | $23.42M | $22.06M | $13.37M | $37.63M | $20.21M | $41.42M | $19.40M | $25.48M |
| QoQ Change | — | -2.2% | -38.8% | +18.5% | +82.8% | +32.3% | -50.9% | -15.8% | -12.7% | +134.6% | +11.3% | -23.8% | +102.7% | -5.8% | -39.4% | +181.5% | -46.3% | +104.9% | -53.1% | +31.3% |
| YoY Change | — | — | — | — | +29.6% | +75.4% | +40.7% | -0.1% | -52.3% | -15.4% | +91.8% | +73.5% | +303.1% | +61.8% | -11.8% | +225.8% | -13.7% | +87.8% | +45.1% | -32.3% |
Range$5.62M – $41.42M
CAGR+23.4%
Avg YoY Growth+56.8%
Median YoY Growth+42.9%
Accounts Payable at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's accounts payable?
- Royalty Pharma (RPRX) reported accounts payable of $25.48M in Q1 2026.
- How has Royalty Pharma's accounts payable changed year-over-year?
- Royalty Pharma's accounts payable decreased by 32.3% year-over-year, from $37.63M to $25.48M.
- What is the long-term trend for Royalty Pharma's accounts payable?
- Over 5 years (2020 to 2025), Royalty Pharma's accounts payable has grown at a 12.5% compound annual growth rate (CAGR), from $10.78M to $19.40M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services.